Valuation : Geron Corporation

Market Cap 867M 747M 708M 641M 1.2B 82.86B 1.21B 8.4B 3.23B 42.16B 3.26B 3.19B 133B P/E 2026 *
-32.1x
P/E 2027 * 19.9x
Enterprise Value 867M 747M 708M 641M 1.2B 82.86B 1.21B 8.4B 3.23B 42.16B 3.26B 3.19B 133B EV / Sales 2026 *
3.67x
EV / Sales 2027 * 2.54x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-1.46%
1 week-14.01%
Current month-9.40%
1 month-14.01%
3 months+17.39%
6 months-15.62%
Current year+2.27%
1 week 1.34
Extreme 1.34
1.58
1 month 1.34
Extreme 1.34
1.62
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
30/06/26 Free

Director

6,103 0.0010%
20/05/26 Free

Director

220,000 0.0343%
20/05/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%-14.01%+6.30%-41.30% 867M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.27B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14.01B
Average -0.41%-4.05%+28.21%+218.59% 27.13B
Weighted average by Cap. -0.56%-2.86%+31.17%+170.01%

Financials

2026 *2027 *
Net sales 236M 204M 193M 175M 328M 22.57B 329M 2.29B 880M 11.48B 887M 868M 36.29B 342M 295M 279M 253M 474M 32.67B 477M 3.31B 1.27B 16.62B 1.28B 1.26B 52.52B
Net income -27.18M -23.42M -22.17M -20.1M -37.71M -2.6B -37.9M -263M -101M -1.32B -102M -99.84M -4.17B 50.14M 43.2M 40.91M 37.08M 69.56M 4.79B 69.92M 486M 187M 2.44B 188M 184M 7.7B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
11/09/26 $1.350 -1.46% 9,867,666
10/09/26 $1.370 -2.14% 7,694,587
09/09/26 $1.400 -7.28% 9,244,762
08/09/26 $1.510 -3.82% 8,306,118
04/09/26 $1.570 +3.97% 11,478,945
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.350USD
Average target price
4.250USD
Spread / Average Target
+214.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!